Citations

Showing 10 of 108162 citations.

Criteria for Biopsy Diagnosis of Minimal Volume Prostatic Adenocarcinoma
Iczkowski, Kenneth A. , Bostwick, David G.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 1 | Pages: 98-107

10.5858/2000-124-0098-cfbdom | PMID 10629139 Get It

Abstract Context. —Minimal volume prostatic adenocarcinoma (defined as involving less than 5% of biopsy tissue) is diagnosed increasingly today because of successful cancer screening. We previously described the diagnostic category called atypical small acinar proliferation (ASAP), suspicious for but not diagnostic of malignancy, present in about 2.5% of routine prostatic needle biopsy specimens. Objective. —To establish the criteria enabling a distinction between ASAP and cancer. Design. —We prospectively evaluated clinical and histologic findings from all 319 patients consecutively diagnosed as having ASAP or minimal cancer by prostatic needle biopsy in a consultation service. Seventeen histopathologic features were assessed. Results. —Fifty-six patients (18%) had ASAP, and 100 (31%) had minimal cancer; the remaining 163 (51%) had benign diagnoses, high-grade prostatic intraepithelial neoplasia, or larger amounts of cancer. The mean age of patients with ASAP did not differ from that of patients with minimal cancer (64.2 years vs 63.3 years; P = .65). In 10 of 17 histopathologic findings, ASAP differed significantly from minimal cancer. Among architectural findings, ASAP foci averaged 0.4 vs 0.8 mm ( P < .0001) and comprised a mean of 11 vs 17 acini ( P < .0001). Infiltrative growth occurred in 75% of ASAP foci and 100% of minimal cancers ( P < .0001). Among cytologic findings, ASAP was significantly less likely than cancer to have mitotic figures (0% vs 10%, respectively; P < .01) or prominent nucleoli in at least 10% of cells (55% vs 100%, respectively; P < .0001) and showed more frequent nuclear hyperchromasia (44% vs 9%, respectively; P < .0001) and less nuclear enlargement ( P = .0002). Luminal blue mucin secretions were less common in ASAP than cancer (6% vs 33%, respectively; P < .0001), but eosinophilic granular secretions and crystalloids were about equally frequent. Concomitant high-grade prostatic intraepithelial neoplasia was present in 23% of ASAP cases and 57% of cancers ( P < .0001). Moderate-to-severe atrophy confounded 59% of cases with ASAP and 35% of cancers ( P = .003); both ASAP foci and cancer were associated with inflammation in about a quarter of cases. In each case with ASAP, we stratified our level of suspicion among 3 categories (favor benign, uncertain, and favor carcinoma). As suspicion increased so did the mean nuclear enlargement and percentage of cases with infiltrative growth and nuclear hyperchromasia (all P < .05). Conclusions. —These criteria, which differ significantly between ASAP and minimal volume cancer, can help to separate patients for whom a second biopsy is recommended from candidates for prostatectomy or other therapy.
Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens
Kavanaugh, Arthur, Tomar, Russell H., Reveille, John D. , Solomon, Daniel H. , Homburger, Henry A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 1 | Pages: 71-81

10.5858/2000-124-0071-gfcuot | PMID 10629135 Get It

Abstract The following guideline presents a series of recommendations based on published medical literature for use of the antinuclear antibody (ANA) test and tests for specific autoantibodies to nuclear antigens in the diagnostic evaluation, prognostic assessment, and monitoring of patients with systemic rheumatic diseases. The guideline emphasizes the need for clinical evaluation to improve the usefulness of test results in patient management. Consideration is given to appropriate use of the generic ANA test in the initial evaluation of patients with signs and symptoms of a systemic rheumatic disease, the evaluation of patients suspected of having lupus erythematosus, use in clinical situations in which the ANA test is required to establish a disease diagnosis, and identification of clinical situations in which the ANA test has little value. Sections are also devoted to recommendations aimed at improving the analytic methods used to detect and measure ANA and specific autoantibodies to nuclear antigens and to the appropriate use of tests for specific autoantibodies in several disease situations that commonly occur in patients with suspected or documented systemic rheumatic diseases. Emphasis is placed on the use of these tests only in situations in which the test results can be expected to provide information necessary for clinical decision making. Those tests of limited medical usefulness and situations in which test results are likely to be misleading are also identified.
Munchausen Syndrome Presenting as Pulmonary Talcosis
Egan, Michael , Tazelaar, Henry D. , Abell-Aleff, Patrice C., Tazelaar, Henry D. , Myers, Jeffrey L.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | January 28, 2021 | Volume: 123 | Issue: 8 | Pages: 736-738

10.5858/1999-123-0736-mspapt | PMID 10420234 Get It

Abstract We describe a patient with self-induced inhalational pulmonary talcosis originally diagnosed as asthma. A 35-year-old female respiratory technologist developed severe asthma that was refractory to steroids and methotrexate. An open lung biopsy specimen showed scattered aggregates of refractile golden crystals within membranous and respiratory bronchioles. The particles ranged in size from 30 to 100 μm and were birefringent when viewed with polarized light. Following review of the lung biopsy specimen, the patient admitted to regularly inhaling large amounts of hospital baby powder. Analysis of the lung biopsy specimen and a sample of the hospital baby powder by x-ray energy dispersion showed identical spectroscopic peaks, including elemental peaks for magnesium silicate. Many patients with self-induced illness lack the picturesque symptomatology classically attributed to Munchausen syndrome. Awareness of these more subtle and varied patterns of presentation may aid in earlier recognition.
Patient factors associated with oral generic olanzapine initiation and substitution among Medicaid beneficiaries: a new user cohort study
Mishuk, Ahmed Ullah, Li, Chao , Huo, Nan , Harris, Ilene, Kiptanui, Zippora , Qian, Jingjing , Qian, Jingjing , Chen, Li , Hansen, Richard A. , Huo, Nan

Mayo Clinic

Current Medical Research and Opinion | January 28, 2021 | Volume: 37 | Issue: 4 | Pages: 655-664

10.1080/03007995.2021.1882413 | PMID 33507825 Get It

Extensive Analysis of Mosaicism in a Case of Turner Syndrome
Park, Jonathan P., Brothman, Arthur R., Cooley, Linda D. , Dewald, Gordon W., Lundquist, Kurt, Palmer, Catherine G., Patil, Shivanand R., Rao, Kathleen W., Saikevych, Irene A., Schneider, Nancy R., Vance, Gail H. , Butler, Merlin G.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | January 28, 2021 | Volume: 123 | Issue: 5 | Pages: 381-385

10.5858/1999-123-0381-eaomia | PMID 10235494 Get It

Abstract Objective. —To assemble and interpret karyotype data provided as part of the College of American Pathologists/American College of Medical Genetics Cytogenetics Proficiency Testing Program. Data Sources, Extraction, and Synthesis. —The Cytogenetics Resource Committee requested data on all cells analyzed in a 1994 whole-blood specimen challenge. In that study, 287 participating laboratories analyzed a total of 14297 cells derived from a sample drawn from an adult donor with Turner syndrome. This individual had previously been found to have mosaicism, including cell lines with X structural anomalies along with monosomy X, making this an excellent challenge for a multicenter cytogenetic survey. Results and Conclusions. —Analysis of the data from this extensive study revealed mosaicism of up to 10 different sex chromosome complements involving the X chromosome with and without a small ring X or a derivative X chromosome. In the routine cytogenetic analysis performed by the participating laboratories, cell lines observed, in decreasing order of prevalence, included 45,X (n = 8357 cells), 46,X,r(X) (n = 3597), 46,X,der( X )t( X ;X) (n = 2237), 46,XX (n = 93), 47,X,r(X),r(X) (n = 5), 47,X,der( X )t( X ;X),der( X )t( X ;X) (n = 3), 47,XX,r(X) (n = 2), and one observation each of 47,XX,der( X )t( X ;X), 47,X,der( X )t( X ;X),r(X), and 47,XXX. Our molecular cytogenetic data, as well as detailed analysis of G-banded chromosomes, suggest the nomenclature for these 2 abnormal X chromosomes as r(X)(p11.3q21.3) and der( X )t( X ;X)(p11.3;q21.3), and we discuss models for the concomitant formation of these 2 entities. Both the degree of analysis and the extensive mosaicism that was discovered in this study are exceptional, and similar reported cases as well as possible mechanisms for the observed X chromosome instability are reviewed.
Sequence of Testing for Monoclonal Gammopathies
Kyle, Robert A.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | January 28, 2021 | Volume: 123 | Issue: 2 | Pages: 114-118

10.5858/1999-123-0114-sotfmg | PMID 10050783 Get It

Abstract The first test for recognition of monoclonal gammopathies should be serum protein electrophoresis with high-resolution agarose gel. Serum protein electrophoresis should be performed whenever multiple myeloma, Waldenström’s macroglobulinemia, primary amyloidosis, or a related disorder is suspected. Immunofixation is critical for the differentiation of a monoclonal from a polyclonal increase in immunoglobulins. Quantitation of immunoglobulins should be performed with a rate nephelometer. The viscosity of serum should be measured if the patient has signs or symptoms of hyperviscosity syndrome. A 24-hour urine specimen should be obtained for determination of the total amount of protein excreted each day. Immunofixation of the urine should be performed on every patient who has an M-protein level greater than 1.5 g/dL (15 g/L) in the serum or in whom multiple myeloma, Waldenström’s macroglobulinemia, primary amyloidosis, or a related disorder is suspected.
Guidelines for Clinical and Laboratory Evaluation of Patients With Monoclonal Gammopathies
Keren, David F. , Alexanian, Raymond , Goeken, James A., Gorevic, Peter D., Kyle, Robert A. , Tomar, Russell H.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | January 28, 2021 | Volume: 123 | Issue: 2 | Pages: 106-107

10.5858/1999-123-0106-gfcale | PMID 10050781 Get It

Abstract This guideline provides the recommendations of an expert panel for the clinical and laboratory evaluation of patients suspected of having a clinical condition that produces a monoclonal protein in serum or urine. The recommendations describe the clinical conditions in which a monoclonal protein should be sought, the optimal sequence of testing to diagnose and monitor these patients, and the most effective laboratory procedures.
Protocol for the Examination of Specimens From Patients With Carcinomas of Renal Tubular Origin, Exclusive of Wilms Tumor and Tumors of Urothelial Origin
Farrow, George M., Amin, Mahul B., Amin, Mahul B.

Mayo Clinic

Archives of Pathology and Laboratory Medicine | January 28, 2021 | Volume: 123 | Issue: 1 | Pages: 23-27

10.5858/1999-123-0023-pfteos | PMID 9923832 Get It

Determinants of Plasma Fibrin D-Dimer Sensitivity for Acute Pulmonary Embolism as Defined by Pulmonary Angiography
Heit, John A. , Minor, Thomas A., Andrews, James C., Nichols, William L., Andrews, James C., Larson, Dirk R. , Li, Hongzhe

Mayo Clinic

Archives of Pathology and Laboratory Medicine | January 28, 2021 | Volume: 123 | Issue: 3 | Pages: 235-240

10.5858/1999-123-0235-dopfdd | PMID 10086512 Get It

Abstract Background. —The reported operating characteristics of the plasma fibrin D-dimer level for the diagnosis of acute pulmonary embolism vary widely. Objective. —To determine the sensitivity, specificity, predictive value, and clinical utility of the D-dimer for the diagnosis of pulmonary embolism, and to describe the effect of D-dimer assay method (enzyme-linked immunosorbent assay [ELISA], latex agglutination, membrane ELISA) and discriminate level, patient location at onset, comorbid disease, duration and intensity of concurrent heparin administration, and duration of symptoms on these operating characteristics. Design. —Prospective laboratory investigation. Setting. —Community and tertiary care teaching hospital. Patients. —Consecutive patients with suspected acute pulmonary embolism referred for pulmonary angiography from April 1993 through March 1996. Measurements. —Baseline characteristics, the duration and intensity of heparin anticoagulation, the time interval between symptom onset and plasma D-dimer testing, pulmonary angiography, and the D-dimer level on the day of pulmonary angiography. Results. —Of 105 consenting patients, 33 (31%) had a positive pulmonary angiogram. The D-dimer sensitivity/negative predictive value for the ELISA, latex agglutination (American Bioproducts Co/Diagnostica Stago and Biopool International), and membrane ELISA were 100%/100%, 94%/94%, 100%/100%, and 97%/96%, respectively, at a discriminate level of 250 μg/L or less. The clinical utility, defined as the prevalence of a negative test, ranged from 17% to 33%. D-dimer sensitivity was unaffected by patient location at onset, comorbid disease, or heparin therapy but was inversely related to the duration of symptoms. Conclusions. —The sensitivity of the plasma fibrin D-dimer for the diagnosis of pulmonary embolism depends on the assay method, the assay-specific discriminate level, and the duration of symptoms. At the appropriate discriminate level, the plasma D-dimer is a sensitive but nonspecific test for the diagnosis of pulmonary embolism.
Characterization of knee dysfunction and related risk factors during pregnancy
Tanaka, Miho J. , Forman, Jared M., Otwell, Alexandra G., Frischmann, Leah, Jones, Lynne C. , Szymanski, Linda M. , Szymanski, Linda M

Mayo Clinic

The Physician and Sportsmedicine | January 28, 2021 | Volume: 50 | Issue: 1 | Pages: 78-83

10.1080/00913847.2021.1882277 | PMID 33507121 Get It